The impact of public health policy to reduce the spread of COVID-19 on access to surgical care is poorly defined. We aim to quantify the surgical backlog during the COVID-19 pandemic in the Brazilian public health system and determine the relationship between state-level policy response and the degree of state-level delays in public surgical care. Monthly estimates of surgical procedures performed per state from January 2016 to December 2020 were obtained from Brazil's Unified Health System Informatics Department. Forecasting models using historical surgical volume data before March 2020 (first reported COVID-19 case) were constructed to predict expected monthly operations from March through December 2020. Total, emergency, and elective surgical monthly backlogs were calculated by comparing reported volume to forecasted volume. Linear mixed effects models were used to model the relationship between public surgical delivery and two measures of health policy response: the COVID-19 Stringency Index (SI) and the Containment & Health Index (CHI) by state. Between March and December 2020, the total surgical backlog included 1,119,433 (95% Confidence Interval 762,663–1,523,995) total operations, 161,321 (95%CI 37,468–395,478) emergent operations, and 928,758 (95%CI 675,202–1,208,769) elective operations. Increased SI and CHI scores were associated with reductions in emergent surgical delays but increases in elective surgical backlogs. The maximum government stringency (score = 100) reduced emergency delays to nearly zero but tripled the elective surgical backlog. Strong health policy efforts to contain COVID-19 ensure minimal reductions in delivery of emergent surgery, but dramatically increase elective backlogs. Additional coordinated government efforts will be necessary to specifically address the increased elective backlogs that accompany stringent responses.
Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare lysosomal storage disorder caused by pathogenic variants in the IDS gene. This condition has specific treatment; therefore, timely diagnosis and adequate follow-up are essential for optimizing patient outcomes. Objective: To synthesize the available evidence on diagnostic and follow-up approaches for MPS II. Methods: Scoping review of ten databases for articles published between 2017 and 2022. Studies involving human participants were included if they addressed diagnostic or follow-up methods for MPS II. We followed the PRISMA-ScR guidelines and conducted qualitative analysis and descriptive statistics to identify trends in diagnostic and follow-up practices. Results: 31 articles were selected. Of these, 23 reported clinical findings, with most articles focusing on neurological (n = 17), skeletal and limbs (n = 16), and head and neck (n = 15) manifestations. Enzyme activity testing was the most reported diagnostic method, although the techniques used were frequently unspecified. Follow-up approaches included imaging studies, clinical assessments, and quality-of-life measurement scales. However, the lack of standardization in methodologies limits the generalizability of findings. Conclusion: This review highlights the need for standardized diagnostic and follow-up protocols for MPS II. Greater transparency in reporting diagnostic methods and a consistent follow-up framework are critical to improving patient care and facilitating research comparisons.